The increased investment in cancer has brought a new era of treatments to the forefront including cell and gene therapies, antibody drug conjugates, checkpoint inhibitors and more. Looking ahead, the industry still has to overcome key hurdles in order to continue expanding access and improving outcomes.

INCLUDED IN THIS TRENDLINE

• Cancer R&D is shifting — here’s what’s changing most
• Zai Lab looks to expand beyond China and make a global impact in oncology
• How Takeda finds the hottest new science to fuel its oncology work